Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Ann Clin Microbiol Antimicrob ; 19(1): 38, 2020 Aug 20.
Article in English | MEDLINE | ID: mdl-32819355

ABSTRACT

Nocardia takedensis was first isolated in 2005, from soil in Japan. We report here two cases of lymphangitis in France (2012-2017) caused by N. takedensis both occurring after skin injury while gardening, which enabled its inoculation. The two patients were immunocompromised and successfully treated by an antimicrobial agent active on the isolated strain, trimethoprim-sulfamethoxazole and amoxicillin-clavulanic acid for patient one and patient two, respectively. Our study along with previous ones supports the idea of a newly recognized cutaneous opportunistic pathogen and reinforces the recommendation of using gloves during soil exposure for immunocompromised patients. Lastly, according to data found in the literature, we would recommend trimethoprim-sulfamethoxazole as an efficient empirical antibiotic therapy in case of cutaneous infection caused by N. takedensis.


Subject(s)
Lymphangitis/diagnosis , Lymphangitis/microbiology , Nocardia Infections/diagnosis , Nocardia Infections/microbiology , Nocardia/isolation & purification , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , France , Gardening , Humans , Male , Middle Aged , Nocardia Infections/drug therapy , Skin Diseases, Infectious/diagnosis , Skin Diseases, Infectious/drug therapy , Skin Diseases, Infectious/microbiology , Soft Tissue Infections/diagnosis , Soft Tissue Infections/drug therapy , Soft Tissue Infections/microbiology
2.
Br J Haematol ; 165(3): 392-401, 2014 May.
Article in English | MEDLINE | ID: mdl-24479958

ABSTRACT

Minimal residual disease (MRD) is a major predictive factor of the cure rate of acute lymphoblastic leukaemia (ALL). Haematopoietic cell transplantation is a treatment option for patients at high risk of relapse. Between 2005 and 2008, we conducted a prospective study evaluating the feasibility and efficacy of the reduction of immunosuppressive medication shortly after a non-ex vivo T depleted myeloablative transplantation. Immunoglobulin (Ig)H/T-cell receptor MRD 30 d before transplant could be obtained in 122 of the 133 cases of high-risk paediatric ALL enrolled. There were no significant demographic differences except remission status (first or second complete remission) between the 95 children with MRD <10(-3) and the 27 with MRD ≥10(-3) . Multivariate analysis identified sex match and MRD as being significantly associated with 5-year survival. MRD ≥10(-3) compromised the 5-year cumulative incidence of relapse (43·6 vs. 16·7%). Complete remission status and stem cell source did not modify the relationship between MRD and prognosis. Thus, pre-transplant MRD is still a major predictor of outcome for ALL. The MRD-guided strategy resulted in survival for 72·3% of patients with MRD<10(-3) and 40·4% of those with MRD ≥10(-3).


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hematopoietic Stem Cell Transplantation/methods , Neoplasm, Residual/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adjuvants, Immunologic/administration & dosage , Adolescent , Child , Child, Preschool , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Male , Neoplasm, Residual/immunology , Neoplasm, Residual/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Prognosis , Prospective Studies , Remission Induction , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL